<DOC>
	<DOCNO>NCT00591526</DOCNO>
	<brief_summary>The first purpose randomize trial compare best treatment group APL 93 trial ( ATRA early introduction anthracycline-AraC chemotherapy , follow 2 consolidation anthracycline-AraC course maintenance combine continuous chemotherapy intermittent ATRA ) regimen , without AraC . It hop investigational arm , anthracycline alone chemotherapy ( without AraC ) , reduce toxicity without increase incidence relapse , comparison classical induction/consolidation anthracycline-AraC regimen Thus : main end point first randomization relapse 2 year secondary end point : complete remission rate ; survival event free survival 2 year , quality-adjusted survival ( Q-TWiST ) . 2 ) Because patient initial WBC count &gt; 10000/mm3 ( ie high count APL ) appear remain relatively high risk relapse even current reference treatment , include trial ass reduction chemotherapy . On contrary : ) receive standard chemotherapy ( best treatment group APL 93 trial ) ; Thus : main end point second randomization relapse 2 year secondary end point : survival event free survival 2 year 3 ) Elderly patient initial WBC ≤ 10000/m3 receive consolidation chemotherapy without AraC first chemotherapy course , reduced dos AraC second third course , follow G-CSF .</brief_summary>
	<brief_title>A Randomized Trial Assessing Roles AraC Newly Diagnosed APL Promyelocytic Leukemia ( APL )</brief_title>
	<detailed_description>All patient receive induction treatment ATRA first chemotherapy course , follow two consolidation chemotherapy course maintenance continuous low dose chemotherapy intermittent ATRA . Initial stratification base age WBC count . Patients age 60 year initial WBC 10 00 receive reference AraC+ group ( Group A ) ( randomization ) . Patients initial WBC &gt; 10000/mm3 initially treat accord AraC+ group . Patients &gt; 60 year initial WBC ≤ 10000/mm3 ) register , without randomization ( Group D ) receive reference AraC+ group , without AraC first chemotherapy course , reduced dos AraC second third course , follow G-CSF . .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>diagnosis APL base morphological ground , confirm presence ( 15 ; 17 ) and/or PMLRARα rearrangement ( RTPCR APL perform center , send fresh cell Prof.C.Chomienne , Centre Hayem , Hopital St.Louis , 1 av . Claude Vellefaux , 75475 PARIS keep frozen RNA [ frozen cell , RNA yield PMLRAR often poor cell ] ) . untreated patient contraindication intensive chemotherapy ( especially cardiac contraindication daunorubicin ) female patient : absence pregnancy adequate contraceptive method ( due teratogenetic effect ATRA early pregnancy ) write informed consent . patient already treat patient contraindication intensive chemotherapy , especially cardiac contraindication daunorubicin female patient : pregnancy absence adequate contraceptive method</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>APL</keyword>
</DOC>